Physician profile
William D Kirk
NPI 1972595270
$12,726.33
in general payments reported to CMS, 2019-2025
49 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,290 · 2020: $1,988 · 2021: $2,004 · 2022: $1,804 · 2023: $1,667 · 2024: $1,399 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,641.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,073.86 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,007.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $962.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $935.22 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $899.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $877.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $678.06 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $554.33 | 2019-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.27 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $383.73 | 2022-2025 | Auvelity |
| Amarin Pharma, INC. | $373.01 | 2019-2022 | |
| Pfizer INC. | $371.66 | 2019-2025 | |
| Allergan, INC. | $355.05 | 2019-2020 | |
| Esperion Therapeutics, INC. | $294.51 | 2020-2025 | Nexletol |
| Mylan Specialty L.P. | $290.85 | 2019-2024 | Yupelri |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.